4. The Interplay of Glutamate and the Kynurenine Pathway in Migraine
4.1. Glutamate and Its Receptors
The glutamatergic system is a crucial neurotransmitter system in the brain that involves the neurotransmitter glutamate. Glutamate is the most abundant excitatory neurotransmitter in the CNS and plays a fundamental role in various brain functions, including learning, memory, cognition, neural plasticity, and pain transmission. The receptors of the glutamatergic system are divided into ionotropic and metabotropic receptors. Ionotropic receptors directly mediate the flow of ions across the cell membrane when glutamate binds to them. The three main types of ionotropic glutamate receptors are NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptors. Activating these receptors is essential for processes like fast synaptic transmission and synaptic plasticity. Metabotropic receptors are coupled to intracellular signaling pathways through G-proteins and do not directly mediate ion flow. Instead, they modulate neuronal excitability and can have longer-lasting effects on synaptic transmission and plasticity.
Dysregulation of the glutamatergic system has been implicated in various neurological and neuropsychiatric disorders. For example, excessive glutamate release and subsequent overactivation of glutamate receptors can lead to excitotoxicity, a process associated with neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease, as reviewed by Szalárdy and his colleagues in 2012
[36]. Additionally, abnormalities in the glutamate receptor function have been linked to conditions like schizophrenia, mood disorders, and migraine disorders
[37][38][39] as well. Elevated levels of glutamate have been found in the blood and cerebrospinal fluid in patients with migraine
[40]. Glutamate excitotoxicity is associated with the hyperexcitability of NMDA receptors
[41], which means that high glutamate stimulation causes an excessive amount of calcium ions to enter cells
[42]. These processes have a crucial role in damaging DNA and different cell structures, yielding neuronal cell death. These receptors, principally the NMDA receptors, have an essential role in the pathomechanism of migraine.
The exact function of metabotropic receptors of glutamate in relation to migraines is not well understood. However, it is generally accepted that these receptors categorized under group I primarily contribute to the perception of pain
[43]. This is because they are situated postsynaptically and, when activated, they heighten the brain’s responsiveness to stimuli. Conversely, metabotropic glutamate receptors in groups II and III are positioned presynaptically, and they work to decrease the release of glutamate, resulting in a mainly pain-relieving effect.
4.2. The Kynurenine Pathway
The kynurenine system is a biochemical pathway that involves the metabolism of the amino acid tryptophan. Tryptophan is an essential amino acid, which means that it must be obtained from the diet since the human body cannot synthesize it on its own. The kynurenine pathway is a major route through which tryptophan is metabolized, leading to the production of various metabolites with diverse physiological and immunological functions. The kynurenine pathway starts with the conversion of tryptophan to N-formyl-L-kynurenine by the enzyme indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO), depending on the tissue and the context. N-formyl-L-kynurenine is then further metabolized into L-kynurenine (L-KYN) by formamidase. L-KYN can also be metabolized to kynurenic acid (KYNA) by kynurenine aminotransferases, to anthranilic acid (ANA) by L-kynurenine hydrolase (KYNU), or to 3-hydroxy-L-kynurenine (3-HK) by kynurenine 3-monooxygenase (KMO) as well. ANA and 3-HK are then further degraded to 3-hydroxyanthranilic acid (3-HA), which metabolizes to quinolinic acid (QUIN). 3-HK can be metabolized to xanthurenic acid as well. As the last step of the kynurenine pathway, QUIN is converted to nicotinamide adenine dinucleotide (NAD+).
Kynurenines, particularly KYNA, have been identified as endogenous glutamate receptor antagonists. In line with this, KYNA acts as an opposing agent at the strychnine-insensitive glycine-binding site of NMDARs at lower concentrations
[44]. Conversely, at higher doses, it also functions by obstructing the glutamate-binding site of NMDA receptors
[45]. Furthermore, KYNA elicits mild opposing responses in relation to kainate- and AMPA-sensitive glutamate receptors
[43]. Its influence on AMPA receptor-mediated activity is subject to concentration, demonstrating enhancement at lower levels (ranging from nanomolar to micromolar) and inhibition at elevated levels (ranging from micromolar to millimolar)
[46]. This Janus-face effect has also been proven by electrophysiological investigations on the hippocampus of young rats, so KYNA actually enhances field excitatory postsynaptic potentials
[47].
4.3. The Role of Kynurenine Pathway in Migraine Pathomechanism Connected to Glutamate Receptors
Several animal investigations suggest that kynurenines, as well as their analogs and halogenated derivatives, hold promise as potential therapeutic agents for treating migraines. Due to KYNA’s limited ability to traverse the blood–brain barrier, its analogs and derivatives are under experimental evaluation. Specifically, 4,6-dichlorokynurenine and 4-chlorokynurenine halogenated derivatives are converted into KYNA derivatives (7-chlorokynurenic acid and 5,7-dichlorokynurenic acid), which exhibit heightened affinity for the glycine-binding site of NMDA receptors
[48][49].
In animal studies, the administration of L-KYN and probenecid (an inhibitor of KYNA secretion from the CNS) or KYNA analogs (N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride (KA1) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride (KA2) effectively inhibited NTG-induced morphological and behavioral changes, likely by targeting NMDA receptors
[50][51][52]. This model revealed decreased expression of kynurenine aminotransferase II (KATII), the primary enzyme in KYNA production, upon NTG administration
[53]. Recent research has indicated that NTG influences the expression of other kynurenine pathway enzymes (TDO, IDO, KYNU, and KMO), implying an impact on the kynurenine pathway
[54].
Another animal model involving trigeminal activation and sensitization includes the application of Complete Freund’s Adjuvant (CFA) to the dural surface, inducing inflammation. In this setup, KA1 was observed to alleviate CFA-induced inflammation
[55]. Moreover, the researchers' group has shown that inflammatory soup could induce sterile neurogenic inflammation in the dura mater, leading to an expansion in the region affected by CGRP and transient receptor potential vanilloid 1 (TRPV1) reactive nerve fibers. Furthermore, there was an increase in the count of neuronal nitric oxide synthase (nNOS)-positive cells in the TNC. Prior applications of KYNA exhibited the capacity to regulate the alterations triggered by the inflammatory soup
[56]. In the CFA model, the researchers' group also demonstrated that there was a sustained elevation in the levels of glutamate, KYNA, and L-KYN within the TNC 24 h following CFA treatment. Additionally, in the somatosensory cortex, the researchers observed significant increases in the concentrations of KYNA and serotonin, which strengthens the idea that inflammation can influence the elements of the glutamate and kynurenine system
[57].
The orofacial formalin test, a model for simulating trigeminal activation and sensitization, demonstrated that probenecid reduced nociceptive behavior in rats by potentially increasing KYNA levels
[58]. Recent studies using KA1 and KA2 abolished formalin-induced behavioral and morphological changes, elevating KYNA levels
[59]. Additionally, in the combined NTG and formalin model, KA1 inhibited behavioral and morphological alterations
[60]. In a trigeminal activation electrical stimulation model, reduced KAT immunoreactivity was observed in the rat’s dura mater
[61].
In a CSD model, KA1 and KA2 inhibited CSD wave propagation, likely by targeting glutamate receptors, which play a pivotal role in CSD generation
[62], potentially connecting migraine and CSD.
Stimulation of the trigeminal ganglion with electrical impulses led to notable elevations in levels of pituitary adenylate cyclase-activating polypeptide (PACAP)1–38 immunoreactivity, preproPACAP, and PACAP1–38 mRNA within the TNC. These increases were effectively inhibited when rats were pre-treated with KYNA, KA1, and MK-801
[63], which indicates that there is a connection between the kynurenine system and PACAP.
Notably, levels of kynurenine pathway metabolites were found altered in migraine sufferers. Decreased kynurenine metabolite levels were identified in patients with chronic migraine, cluster headache, and episodic migraine
[64][65][66][67] consistent with findings from animal studies using the NTG migraine model
[53]. These findings suggest that decreased KYNA levels may signify heightened glutamatergic activity in chronic migraine and cluster headache
[68].
The precise role of KYNA and its metabolites in migraine pathomechanisms remains partially understood. KYNA’s effects may occur through peripheral and central mechanisms. Peripherally, KYNA can modulate glutamate receptors, particularly NMDA receptors in the dorsal root and TG
[69]. Beyond peripheral effects, KYNA and analogs impact second-order neurons, as evidenced by KYNA’s reduction of mechanical allodynia and pain sensitivity in tests like the hot-plate and tail-flick tests
[70][71] (
Figure 3).
Figure 3. The role of glutamate and kynurenine system in migraine pathomechanism. AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-methyl-D-aspartate; mGlu, metabotropic glutamate receptor.